Nufenoxole, a new orally active agent ( Fig. 1) , possesses potent antidiarrhoeal properties in both animals and man, with activity comparable to that of diphenoxylate and loperamide.
Nufenoxole, however, has a longer biological half-life and shows a wider separation of gastrointestinal and central nervous system effects.1 3 Animal and human studies have revealed no evidence of dependence liability. 2 Nufenoxole binds to opioid receptors in the brain and myenteric plexus of the intestine.3 Endogenous and exogenous opioids enhance water and electrolyte absorption and inhibit fluid secretion stimulated by a variety of secretagogues in mammalian intestine.413 Although opioids are thought to exert their antidiarrhoeal effects by inhibiting intestinal motility,'1'6 such changes in transmucosal epithelial fluid transport may be at least equally as important in mediating their action. 17 The present study was performed to determine whether nufenoxole inhibits fluid secretion stimulated by the secretagogue, dioctyl sodium sulphosuccinate, DSS,18 19 were taken for immediate bicarbonate estimation and samples for determination of other electrolyte concentrations were stored at -200C before analysis. EXPERIMENT 1 Six subjects were studied using the protocol shown (Fig. 2a) 
The DSS perfusate was infused after administration of both buffer and nufenoxole on both study days. A values refer to the A (DSS post-nufenoxole -DSS post-buffer) on the iv saline and iv naloxone study days respectively. Classically, the antidiarrhoeal activity of opioids has been attributed to their effects on motility, the slowing of intestinal transit increasing the contact time of the luminal contents with the intestinal mucosa, which promotes absorption of water and electrolytes.14 15 In a previous study in man, it was concluded that the antidiarrhoeal action of codeine could be explained entirely by its inhibition of intestinal motility,16 and the antisecretory properties of loperamide have been well documented.5 8A3 Nufenoxole, in common with other opioid antidiarrhoeals, increases circular muscle contractile activity in the intestine,1 which may partly explain its antidiarrhoeal activity.
In the present study, nufenoxole markedly inhibited the effects of the secretagogue, DSS, on water, sodium, and chloride movement in the human jejunum. 
